Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
ACELRX PHARMACEUTICALS INC (ACRX)
|
Add to portfolio |
|
|
|
| Price: |
$1.31
| | Metrics |
| OS: |
16.3
|
M
| |
|
|
| Market cap: |
$21.4
|
M
| |
|
|
|
Net cash:
|
$7.41
|
M
| |
$0.45
|
per share
|
|
EV:
|
$14
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 2.8 | 5.4 | 2.3 | 2.2 | 8.0 | 17.4 | 19.3 | 5.2 |
| Revenue growth | -48.0% | 136.6% | 6.4% | -73.1% | -53.9% | -9.9% | 269.2% | -82.3% |
| Cost of goods sold | 3.8 | 6.0 | 6.8 | 4.0 | 10.7 | 12.3 | 1.8 | 0.0 |
| Gross profit | -0.9 | -0.6 | -4.5 | -1.8 | -2.7 | 5.0 | 17.5 | 5.2 |
| Gross margin | -33.2% | -11.4% | -197.3% | -84.8% | -33.3% | 29.0% | 90.8% | 100.0% |
| Selling, general and administrative | 30.9 | 36.3 | 45.0 | 20.8 | 16.6 | | | |
| Research and development | 4.1 | 4.0 | 4.7 | 13.1 | 19.4 | 21.4 | 22.5 | 24.5 |
| General and administrative | | | | | | 15.6 | 14.2 | 18.3 |
| EBIT | -36.0 | -41.0 | -54.2 | -35.7 | -38.7 | -32.0 | -19.2 | -37.6 |
| EBIT margin | -1276.3% | -756.3% | -2368.1% | -1660.9% | -483.8% | -184.1% | -99.7% | -721.7% |
| Pre-tax income | -35.1 | -40.4 | -53.2 | -47.1 | -52.2 | -43.2 | -23.6 | -33.4 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | -0.7 | 0.0 | 0.8 | 0.0 |
| Tax rate | | | | | 1.3% | 0.1% | | 0.0% |
| Net income | -35.1 | -40.4 | -53.2 | -47.1 | -51.5 | -43.2 | -24.4 | -33.4 |
| Net margin | -1245.5% | -745.6% | -2325.9% | -2192.0% | -644.3% | -248.6% | -126.7% | -639.3% |
| |
| Diluted EPS | ($0.29) | ($0.47) | ($0.67) | ($0.81) | ($1.10) | ($0.95) | ($0.55) | ($0.75) |
| Shares outstanding (diluted) | 119.9 | 85.3 | 79.2 | 58.4 | 46.9 | 45.3 | 44.5 | 44.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|